Search - tctmd.com

Displaying 341 - 360 of 574

Sort: Relevancy | Date

Presentation LAA 2017

LAA and PFO Closure - Interventional Prevention of Cardioembolic Stroke: A Technique-Oriented Course

Presenter: Apostolos Tzikas

July 22, 2017

Presentation LAA 2017

LAA Closure: Shared Decision Making Criteria and Documentation

Presenter: Megan Coylewright

July 21, 2017

Presentation LAA 2017

Can CT Identify the Optimal Location for LAA Puncture and Closure?

Presenter: Jacqueline Saw

July 21, 2017

Presentation LAA 2017

WATCHMAN LAA Closure: Device Description, Implantation Technique, Medications, and Follow-Up

Presenter: Shephal Doshi

July 21, 2017

Presentation LAA 2017

The Spectrum of LAA Closure Devices: Similarities and Differences

Presenter: Horst Sievert

July 21, 2017

Presentation LAA 2017

What Have We Learned from Surgical LAA Closure?

Presenter: Subhasis Chatterjee

July 21, 2017

Presentation LAA 2017

Electrical/Ablation Approaches to AFib: Competitive or Complementary With LAA Closure?

Presenter: Vivek Y. Reddy

July 21, 2017

Presentation EuroPCR 2017

Efficacy and Safety of LAA Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation: 1-year FU of the EWOLUTION trial

Presenter: Lucas Boersma, Martin W. Bergmann

May 18, 2017

Presentation Fellows 2017

LAA Closure: Data, Devices, and Technique

Presenter: Susheel Kodali, Mark Reisman

April 09, 2017

Presentation ECHO 2017

Interventional Echocardiography II: PVL and LAA Closure

Presenter: Omar K. Khalique

April 02, 2017

Presentation SIF 2017

LAA Closure: First or Second Line Therapy.

Presenter: Brij Maini

March 09, 2017

Presentation SIF 2017

LAA Closure with the WATCHMAN Device: A Perfect Case

Presenter: Ramon Quesada,

March 09, 2017

Presentation JIM 2017

Clinical Experience With LAmbre LAA CLOSURE System

Presenter: Horst Sievert

February 09, 2017

Presentation TCT 2016

Management of Residual Leaks After LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw

November 01, 2016

Presentation TCT 2016

Assessment and Implications of Residual Leaks After Percutaneous and Surgical LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw

November 01, 2016

Presentation TCT 2016

Reimbursement Challenges For LAAC: Balancing The Clinical Need Vs. Robust Data Vs. Societal Economic Considerations

Presenter: Aaron V. Kaplan, Rachel Neubrander, Tamara Syrek Jensen

November 01, 2016

Presentation TCT 2016

Follow-up Evaluation After LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw, Bushra S Rana

November 01, 2016

Presentation TCT 2016

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Presenter: Aaron V. Kaplan, Rachel Neubrander, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Trial Designs For LAA Closure: Potential Regulatory Pathways and Unanswered Questions What FDA Would Like to See

Presenter: Aaron V. Kaplan, Rachel Neubrander, Katherine Wallon

November 01, 2016

Presentation TCT 2016

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White

November 01, 2016

Advertisement

LAA and PFO Closure - Interventional Prevention of Cardioembolic Stroke: A Technique-Oriented Course

LAA Closure: Shared Decision Making Criteria and Documentation

Can CT Identify the Optimal Location for LAA Puncture and Closure?

WATCHMAN LAA Closure: Device Description, Implantation Technique, Medications, and Follow-Up

The Spectrum of LAA Closure Devices: Similarities and Differences

What Have We Learned from Surgical LAA Closure?

Electrical/Ablation Approaches to AFib: Competitive or Complementary With LAA Closure?

Efficacy and Safety of LAA Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation: 1-year FU of the EWOLUTION trial

LAA Closure: Data, Devices, and Technique

Interventional Echocardiography II: PVL and LAA Closure

LAA Closure: First or Second Line Therapy.

LAA Closure with the WATCHMAN Device: A Perfect Case

Clinical Experience With LAmbre LAA CLOSURE System

Management of Residual Leaks After LAA Closure

Assessment and Implications of Residual Leaks After Percutaneous and Surgical LAA Closure

Reimbursement Challenges For LAAC: Balancing The Clinical Need Vs. Robust Data Vs. Societal Economic Considerations

Follow-up Evaluation After LAA Closure

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Trial Designs For LAA Closure: Potential Regulatory Pathways and Unanswered Questions What FDA Would Like to See

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content